(Q40464404)

20 September 2017

title

Fulvestrant - a new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. (English)

1 reference

20 September 2017

Kurt Possinger

1

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 December 2004

1 reference

Expert Opinion on Pharmacotherapy

20 September 2017

published in

1 reference

20 September 2017

volume

5

1 reference

20 September 2017

issue

12

1 reference

20 September 2017

page(s)

2549-2558

1 reference

ABC of breast diseases: breast cancer

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Tamoxifen--an update on current data and where it can now be used

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Pharmacokinetics of a single dose of fulvestrant prolonged-release intramuscular injection in postmenopausal women awaiting surgery for primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.5.12.2549

10.1517/14656566.5.12.2549

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference